Telitacicept demonstrated significant clinical efficacy and a favorable safety profile in patients with ILD associated with antisynthetase syndrome, rheumatoid arthritis, and Sjögren's syndrome. These findings suggest telitacicept may be a promising therapeutic option for refractory or complex connective tissue disease-associated ILD.
Chen et al. (Thu,) studied this question.